I heard about Dr. [Denitsa] Milanova a few years back when she just joined Harvard, and met her for the first time in person in May 2022 when she told me about her new exciting venture – Marble Therapeutics and her quest to use genetic engineering to target aging.
[newletter]Denitsa says that her team is developing methods to drive rejuvenation of skin cells with gene therapy and is working on a product that could reverse wrinkles like a genetic Botox.
The magic words in longevity biotech nowadays are platform and pipeline, where the company develops a platform for drug discovery and is using this platform to discover and develop its own therapeutic programs. And Marble is building target discovery and delivery platforms to drive its first pipeline program in the skin.
…
Marble is starting with skin rejuvenation, but they aren’t trying to be just a skin company. “Think of deep-omic profiling of skin, blood, muscle, even reproductive cells with a time stamp on it,” Milanova says. “Our vision is to have high-quality cross-sectional and longitudinal datasets and all discoveries being data-driven rather than hypothesis-driven.”
